• At the AACR Annual Meeting, Ryvu is presenting posters on two topics:  

• RVU305: highlighting best-in-class properties of Ryvu’s brain-permeable, MTA-cooperative PRMT5 inhibitor 

• ONCO Prime: highlighting novel synthetic lethal targets for colorectal cancer discovered in Ryvu’s proprietary platform 

• At the ADC Payload Summit, CSO Krzysztof Brzózka will give an oral presentation on Ryvu’s next-generation payloads. 

Krakow, Poland – April 25, 2025 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on innovative therapies targeting emerging areas in oncology, is presenting preclinical data from its synthetic lethality pipeline at the 2025 AACR Annual Meeting, April 25 to April 30, 2025 in Chicago, IL. Additionally, the company will give an oral presentation on Ryvu’s ADC (antibody-drug conjugate) payload innovation at the 2nd ADC Payload Summit, May 6 to May 8, 2025, in Boston, MA. 

“We are excited to showcase continued progress across our preclinical pipeline. In particular, we are rapidly advancing RVU305, our potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, with IND/CTA-enabling studies on track for completion in H2 2025. In addition, our proprietary ONCO Prime platform has identified several novel synthetic lethal targets, including targets for KRAS-driven tumors, which offer immense potential to transform cancer treatment. We are also developing innovative next-generation ADCs with new payload classes,” said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.  

 

Details on poster presentations are as follows: 

Poster Title: “Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment.”
Session Name: HDAC and Methyltransferase Inhibitors
Session date and time: Tuesday, April 29, 9:00 AM – 12:00 PM EST
Poster Number:17  

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant potential in targeting MTAP-deleted cancers. In preclinical studies, RVU305 effectively inhibited tumor growth in MTAP-null cancer models without affecting normal cells. RVU305 also demonstrated CNS penetration with predicted efficacious exposure in the brain in cynomolgus monkeys. In CNS cell lines, RVU305 exhibited high potency and efficacy. Furthermore, co-treatment with an anti-PD-1 antibody was well tolerated and resulted in antitumor activity in an MTAP-deleted model resistant to immune checkpoint inhibitors (ICI). The efficacy of RVU305 was supported by pharmacodynamic changes observed in tumor tissue. These results position RVU305 as a promising therapeutic option for patients carrying MTAP-deleted cancers resistant to ICI. 

Poster Title: “Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies.”
Session Name: Experimental and Molecular Therapeutics
Session date and time: Monday, April 28, 2:00 PM – 5:00 PM EST
Poster Number: 3  

This study highlights the discovery and validation of novel therapeutic targets for colorectal cancer (CRC) through synthetic lethal (SL) interactions, addressing the urgent need for more effective and personalized treatment options. The team identified key vulnerabilities in CRC using advanced models, including genetically engineered human intestinal stem cells (hISCs) and patient-derived xenografts (PDXs) in combination with CRISPR/Cas9 technology. 

Genome-wide SL screens revealed targets associated with common CRC driver mutations, particularly APC and KRAS. These findings were robustly validated. Notably, knock-out of the identified target selectively killed mutant patient-derived cells while sparing healthy intestinal stem cells, demonstrating a favorable therapeutic window. 

Furthermore, we identified small-molecule inhibitors that block the activity of the newly discovered target. These compounds modulate downstream biomarkers and phenocopy the differential effects observed in our genetic studies, supporting this approach’s translational potential. 

Together, these results lay the groundwork for developing targeted therapies tailored to the genetic makeup of CRC tumors. 

All posters are now available online and can be obtained from the conference site:  https://www.aacr.org/  

Ryvu will also present at the 2nd ADC Payload Summit in Boston, MA, May 6-8, 2025. Krzysztof Brzózka, CSO of Ryvu Therapeutics, will give an oral presentation on “Exploring Next-Generation Payload Diversity Beyond Cytotoxics to Diversify Immune-oncology MOAs”. The session will showcase Ryvu’s innovative approach to expanding the diversity of payloads in antibody-drug conjugates (ADCs). Dr. Brzózka will discuss the company’s approach to identifying new small-molecule payloads with conjugation potential, highlighting how matching target biology with the appropriate payload can optimize therapeutic outcomes. This presentation reflects Ryvu’s commitment to advancing ADC technologies and expanding immuno-oncology modalities for broader cancer treatment opportunities. 

More information: https://adc-payload.com/conference-day-two/